Goldman identifies three bears that could disrupt the Goldilocks market environment
After a stunning comeback for markets and sentiment, Goldman Sachs places three main risks in the spotlight
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Verona Pharma’s stock soars toward a record after $10 billion buyout deal with Merck.
Why interest-rate cuts won’t be the fuel the stock market needs to rocket higher
There’s no consistent pattern to how the stock investors react when the Fed lowers rates.
Why this veteran advisor says it’s speculative not to have crypto in portfolios
Ric Edelman argues that the time to invest in cryptocurrencies is now, while 95% of the world is still asleep.
What will it take for the Fed to cut rates in September? Look here for clues.
Economists will be reading the minutes of the Federal Reserve’s June meeting to get a sense of what might have to happen in order for the central bank to cut interest rates in September.